Protective effects of astragaloside iv on db/db mice with diabetic retinopathy

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Ding, Yuzhi ^a   Yuan, Songtao ^a   Liu, Xiaoyi ^a   Mao, Pingan ^b   Zhao, Chen ^a   Huang, Qiong ^a   Zhang, Rihua ^a   Fang, Yuan ^a   Song, Qinglu ^a   Yuan, Dongqing ^a   Xie, Ping ^a   Liu, Yun ^a   Liu, Qinghuai ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED CHANGZHOU NO 2 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ASTRAGALOSIDE IV; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ASTRAGALOSIDE A; SAPONIN; TRITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; ELECTRORETINOGRAPHY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EYE PROTECTION; GLUCOSE BLOOD LEVEL; LOW DRUG DOSE; MALE; MOUSE; NICK END LABELING; NONHUMAN; QUANTITATIVE ANALYSIS; RETINA GANGLION CELL; WESTERN BLOTTING; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

MUS;

ALDEHYDE REDUCTASE; ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; MAP KINASE SIGNALING SYSTEM; MICE; NF-KAPPA B; PHOSPHORYLATION; RETINAL GANGLION CELLS; SAPONINS; TRITERPENES;

EID: 84911998139     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112207     Document Type: Article

References (57)

1. Madsen-Bouterse SA, Kowluru RA (2008) Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Reviews in endocrine & metabolic disorders 9: 315-327.
2. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, et al. (2006) Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55: 2401-2411.
3. Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376: 124-136.
4. Romero-Aroca P, Sagarra-Alamo R, Basora-Gallisa J, Basora-Gallisa T, Baget- Bernaldiz M, et al. (2010) Prospective comparison of two methods of screening for diabetic retinopathy by nonmydriatic fundus camera. Clinical ophthalmology 4: 1481-1488.
5. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, et al. (2004) Global data on visual impairment in the year 2002. Bulletin of the World Health Organization 82: 844-851.
6. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England journal of medicine 329: 977-986.
7. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853.
8. Newman EA (2003) New roles for astrocytes: regulation of synaptic transmission. Trends in neurosciences 26: 536-542.
9. Bearse MA Jr, Han Y, Schneck ME, Barez S, Jacobsen C, et al. (2004) Local multifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy. Investigative ophthalmology & visual science 45: 3259-3265.
10. Han Y, Adams AJ, Bearse MA Jr, Schneck ME (2004) Multifocal electroretinogram and short-wavelength automated perimetry measures in diabetic eyes with little or no retinopathy. Archives of ophthalmology 122: 1809-1815.
11. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, et al. (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. The Journal of clinical investigation 102: 783-791.
12. Abu-El-Asrar AM, Dralands L, Missotten L, Al-Jadaan IA, Geboes K (2004) Expression of apoptosis markers in the retinas of human subjects with diabetes. Investigative ophthalmology & visual science 45: 2760-2766.
13. Park SH, Park JW, Park SJ, Kim KY, Chung JW, et al. (2003) Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia 46: 1260-1268.
14. Zeng XX, Ng YK, Ling EA (2000) Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Visual neuroscience 17: 463-471.
15. Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, et al. (2005) Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 54: 1559-1565.
16. Zhang J, Gerhardinger C, Lorenzi M (2002) Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 51: 3499-3504.
17. Gerhardinger C, Costa MB, Coulombe MC, Toth I, Hoehn T, et al. (2005) Expression of acute-phase response proteins in retinal Muller cells in diabetes. Investigative ophthalmology & visual science 46: 349-357.
18. Tang J, Kern TS (2011) Inflammation in diabetic retinopathy. Progress in retinal and eye research 30: 343-358.
19. Kuzumoto Y1, Kusunoki S, Kato N, Kihara M, Low PA. (2006) Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat. Diabetologia. 49: 3085-3093.
20. Tiwari AK, Kumar DA, Sweeya PS, Chauhan HA, Lavanya V, et al. (2014) Vegetables' juice influences polyol pathway by multiple mechanisms in favour of reducing development of oxidative stress and resultant diabetic complications. Pharmacognosy Magazine. 10: 383-391.
21. Chang KC, Ponder J, Labarbera DV, Petrash JM (2014) Aldose reductase inhibition prevents endotoxin-induced inflammatory responses in retinal microglia. Investigative ophthalmology & visual science. 55: 2853-2861.
22. Noh HL, Hu Y, Park TS, DiCioccio T, Nichols AJ, Okajima K, et al. (2009) Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat. journal of pharmacology and experimental therapeutics. 328: 496-503.
23. Sango K, Suzuki T, Yanagisawa H, Takaku S, Hirooka H, et al. (2006) High glucose-induced activation of the polyol pathway and changes of gene expression profiles in immortalized adult mouse Schwann cells IMS32. Journal of neurochemistry. 98: 446-458.
24. Lv L, Wu SY, Wang GF, Zhang JJ, Pang JX, et al. (2010) Effect of astragaloside IV on hepatic glucose-regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Phytotherapy research: PTR 24: 219-224.
25. Motomura K, Fujiwara Y, Kiyota N, Tsurushima K, Takeya M, et al. (2009) Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products. Journal of agricultural and food chemistry 7: 7666-7672.
26. Gui D, Guo Y, Wang F, Liu W, Chen J, et al. (2012) Astragaloside IV, a Novel Antioxidant, Prevents Glucose Induced Podocyte Apoptosis In Vitro and In Vivo. PLoS One. 2012; 7(6): e39824.
27. Gui D, Huang J, Guo Y, Chen J, Chen Y, et al. (2013) Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-kappaB-mediated inflammatory genes expression. Cytokine 2013;61: 970-977.
28. Yu J, Zhang Y, Sun S, Shen J, Qiu J, et al. (2006) Inhibitory effects of astragaloside IV on diabetic peripheral neuropathy in rats. Canadian journal of physiology and pharmacology 84: 579-587.
29. Porciatti V, Saleh M, Nagaraju M (2007) The pattern electroretinogram as a tool to monitor progressive retinal ganglion cell dysfunction in the DBA/2J mouse model of glaucoma. Investigative ophthalmology & visual science 48: 745-751.
30. Li GY, Fan B, Su GF (2009) Acute energy reduction induces caspase-dependent apoptosis and activates p53 in retinal ganglion cells (RGC-5). Experimental eye research 89: 581-589.
31. Ji Y, Lu G, Chen G, Huang B, Zhang X, et al. (2011) Microcystin-LR Induces Apoptosis via NF-kappaB/iNOS Pathway in INS-1 Cells. International journal of molecular sciences 12: 4722-4734.
32. Yin X, Zhang Y, Wu H, Zhu X, Zheng X, et al. (2004) Protective effects of Astragalus saponin I on early stage of diabetic nephropathy in rats. Journal of pharmacological sciences 95: 256-266.
33. Huang R, Jiang W, Yang J, Mao YQ, Zhang Y, et al. (2010) A biotin label-based antibody array for high-content profiling of protein expression. Cancer genomics & proteomics 7: 129-141.
34. Dong N, Chang L, Wang B, Chu L. (2014) Retinal neuronal MCP-1 induced by AGEs stimulates TNF-a expression in rat microglia via p38, ERK, and NF-kB pathways. Mol Vis. 20: 616-628.
35. Basavarajappa HD, Lee B, Fei X, Lim D, Callaghan B, et al. (2014) Synthesis and mechanistic studies of a novel homoisoflavanone inhibitor of endothelial cell growth. PLoS One. 2014 Apr 21 9(4): e95694.
36. Kim J, Kim CS, Sohn E, Lee YM, Jo K, et al. (2014) Aminoguanidine protects against apoptosis of retinal ganglion cells in Zucker diabetic fatty rats. Eur Rev Med Pharmacol Sci. 18: 1573-1578.
37. Wang S, Li J, Huang H, Gao W, Zhuang C, et al. (2009) Anti-hepatitis B virus activities of astragaloside IV isolated from radix Astragali. Biological & pharmaceutical bulletin 32: 132-135.
38. Luo Y, Qin Z, Hong Z, Zhang X, Ding D, et al. (2004) Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia. Neuroscience letters 363: 218-223.
39. Zhang WJ, Hufnagl P, Binder BR, Wojta J (2003) Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-kappaB activation and adhesion molecule expression. Thrombosis and haemostasis. 90: 904-914.
40. Hummel KP, Dickie MM, Coleman DL (1966) Diabetes, a new mutation in the mouse. Science. 153: 1127-1128.
41. Tesch GH, Lim AK (2011) Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. American journal of physiology Renal physiology. 300: 301-310.
42. Robinson R, Barathi VA, Chaurasia SS, Wong TY, Kern TS (2012) Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Dis Model Mech. 5: 444-456.
43. Clements RS Jr, Robison WG Jr, Cohen MP (1998) Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. J Diabetes Complications. 12: 28-33.
44. Li J, Wang JJ, Chen D, Mott R, Yu Q, et al. (2009) Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes. Exp Eye Res. 89: 71-78.
45. Li J, Wang JJ, Yu Q, Chen K, Mahadev K, et al. (2010) Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Diabetes. 59: 1528-1538.
46. Xiao C, He M, Nan Y, Zhang D, Chen B, et al. (2012) Physiological effects of superoxide dismutase on altered visual function of retinal ganglion cells in db/db mice. PLoS One. 7:e30343.
47. Fletcher EL, Phipps JA, Ward MM, Puthussery T, Wilkinson-Berka JL, et al. (2007) Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des. 13: 2699-2712.
48. Barber AJ, Gardner TW, Abcouwer SF (2011) The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci. 52: 1156-1163.
49. Antonetti DA, Klein R, Gardner TW (2012) Diabetic retinopathy. N Engl J Med. 366: 1227-1239.
50. Cheung AK, Fung MK, Lo AC, Lam TT, So KF, et al. (2005) Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes. 54: 3119-3125.
51. Tang L, Zhang Y, Jiang Y, Willard L, Ortiz E, et al. (2011) Dietary wolfberry ameliorates retinal structure abnormalities in db/db mice at the early stage of diabetes. Exp Biol Med (Maywood). 236: 1051-1063.
52. Bogdanov P, Corraliza L, Villena JA, Carvalho AR, Garcia-ArumíJ, et al. (2014) The db/db mouse: a useful model for the study of diabetic retinal neurodegeneration. PLoS One. 9:e97302.
53. Naeser P, Brolin SE, Berggren PO (1987) The sorbitol shunt in the retina and the optic nerve of mice with inherited and STZ-induced diabetes. Acta Ophthalmol (Copenh). 65: 693-698.
54. Miloso M, Scuteri A, Foudah D, Tredici G (2008) MAPKs as mediators of cell fate determination: an approach to neurodegenerative diseases. Curr Med Chem 15: 538-548.
55. Luo Y, DeFranco DB (2006) Opposing roles for ERK1/2 in neuronal oxidative toxicity: distinct mechanisms of ERK1/2 action at early versus late phases of oxidative stress. J Biol Chem 281: 16436-16442.
56. Vanden-Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, et al. (1995) P38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor- kB p65 transactivation mediated by tumor necrosis factor. Science. 270: 2008-2011.
57. Kim JH, Kim JH, Jun HO, Yu YS, Kim KW (2010) Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy. Am J Pathol. 176: 1517-1524.